CC
EGRX

Centiva Capital’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

Centiva Capital’s Portfolio EGRX Stock Details EGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-7,698
Closed -$218K – 2104
2023
Q1 		$218K Buy
+7,698
New +$229K 0.01% 1196

Other funds holding EGRX

Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.3B AUM 23.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Centiva Capital's EGRX Position: Q2 2023 in Review

Centiva Capital sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q2 2023, closing a stake of 7,698 shares — an estimated $218K sold.

Centiva Capital first reported a position in EGRX in Q1 2023 and held it in 1 quarter. The position peaked at $218K in Q1 2023. 126 funds tracked by Wall St. Rank hold EGRX as of Q2 2023.

  • Centiva Capital reported no remaining Eagle Pharmaceuticals, Inc. position as of Q2 2023 after selling out during the quarter.
  • Centiva Capital sold 7,698 Eagle Pharmaceuticals, Inc. shares in Q2 2023, an estimated $218K.
  • Centiva Capital first reported a position in Eagle Pharmaceuticals, Inc. in Q1 2023 and held it in 1 quarter.
  • Centiva Capital's Eagle Pharmaceuticals, Inc. position peaked at $218K in Q1 2023.
  • 126 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q2 2023.

Based on Centiva Capital's 13F filing for Q2 2023, filed 14 Aug 2023.